Hiroya Hashimoto

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)

Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double‐blind, double‐dummy, active‐controlled, parallel‐group study

Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double‐blind, placebo‐controlled study